Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.52 |
| ▸ | CSF1R | P07333 | 2/20 | 0.51 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3659264 | 0.90 | PAX8 (0.55) | PAX8CSF1RNUDT1EGFRMEN1 | |
| SCHEMBL3792946 | 0.90 | NUDT1 (0.60) | PAX8CSF1RNUDT1EGFRPDE4B | |
| SCHEMBL3785960 | 0.89 | PAX8 (0.52) | PAX8CSF1RNUDT1EGFRCREBBP | |
| SCHEMBL3786537 | 0.87 | PAX8 (0.50) | PAX8NUDT1EGFRMEN1KMT2A | |
| SCHEMBL29744204 | 0.87 | CSF1R (0.55) | PAX8CSF1RNUDT1EGFRPDE4B | |
| SCHEMBL401899 | 0.87 | CSF1R (0.55) | PAX8CSF1RNUDT1EGFRPDE4B | |
| SCHEMBL13076218 | 0.86 | CSF1R (0.58) | PAX8CSF1REGFRPDE4B | |
| Hydrochloric Acid SCHEMBL15094014 | 0.86 | PAX8 (0.56) | PAX8CSF1RNUDT1EGFRPDE4B | |
| SCHEMBL3785514 | 0.86 | PAX8 (0.49) | PAX8CSF1RNUDT1EGFRPDE4B | |
| SCHEMBL402212 | 0.86 | PAX8 (0.67) | PAX8MEN1KMT2ACREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | claimed |
| WO-2013103317-A1 | QUINOLINE COMPOUNDS WHICH ARE ANTI-ANGIOGENIC INTEGRIN ALPHA5 BETAL INHIBITORS FOR USE IN THE TREATMENT OF FIBROSIS OR FIBROSIS-RELATED DISEASES | CLANOTECH AB (SE) | 2013-07-11 | — | — | WO | claimed |
| WO-2010133672-A1 | DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | claimed |
| US-9376393-B2 | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases | CLANOTECH AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-9376393-B2 | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases | CLANOTECH AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-9376393-B2 | Quinoline compounds which are anti-angiogenic integrin alpha5 beta1 inhibitors for use in the treatment of fibrosis or fibrosis-related diseases | CLANOTECH AB (SE) | 2016-06-28 | — | — | US | disclosed |
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | disclosed |
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | CLANOTECH AB (SE) | 2015-01-29 | — | — | US | disclosed |
| EP-2432764-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | ClanoTech AB (SE) | 2012-03-28 | — | — | EP | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2012-03-15 | — | — | US | disclosed |
| WO-2010133669-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133672-A1 | DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010133672-A1 | DERIVATIVES OF QUINOLINE-3-CARBOXYLIC ACID AND THEIR MEDICAL USE | CLANOTECH AB (SE) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031723-A1 | Quinoline Compounds Which Are Anti-Angiogenic Integrin Alpha5 Beta1 Inhibitors for Use in the Treatment of Fibrosis or Fibrosis-Related Diseases | ITGB5, ITGA5, ITGAL | PAX8 381/4885CSF1R 904/4885NUDT1 3611/4885 |
| US-20120065199-A1 | SUBSTITUTED QUINOLINES FOR USE AS VEGF INHIBITORS | FLT1, FLT4, VEGFA | PAX8 1573/4885CSF1R 85/4885NUDT1 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.